announcement of...?, page-3

good result, because:

a) it works, even among HIV/HVC coinfected
b) it does not interfere with HIV medication

Just how attractive it is to potential partners may depend on how the HCV market is eventually sliced and diced.

One possibility is that no one-size-fits-all treatment emerges. Instead different cocktails of drugs may become accepted as standard treatments for different combinations of HCV genotypes/variations of the IL28B gene.

BIT225 has been shown to be 100% effective in combination with PEG/RBV against HCV genotypes 1 and 3, as long as the IL28B expression is homozygous (the good news is that the majority of people infected world wide have homozygous IL28B, including 90% in East Asia).

To complicate things, the failure/slower response in heterozygous IL28B participants is likely due to resistance to interferon, not BIT225. So BIT225's method of action may be fine complementing some of the newer DAA drugs against heterozygous IL28B.

We wait to see how BIT225 fits into the plans of big pharma.

good luck to all